Patents by Inventor JoAnn Hotta

JoAnn Hotta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10336988
    Abstract: A method of purification of non-enveloped or pseudo-enveloped virus produced in vitro uses a composition with at least one detergent. A method of purification can use multiple detergents, and a method of determining the presence and/or level of a non-enveloped or pseudo-enveloped virus in a sample includes treating with at least one detergent.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: July 2, 2019
    Assignee: GRIFOLS, S.A.
    Inventors: Brett Buno, Terri Journigan, Joann Hotta, Michael Burdick
  • Patent number: 10208291
    Abstract: Polybrene as an additive in cell culture medium is used in methods for the generation of high-titer hepatitis E virus stocks and assays for titration of hepatitis E virus. A cell culture medium containing polybrene is used for high-titer HEV generation, a method for determining the presence and/or the level of HEV in a sample, and an HEV titration assay using polybrene.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: February 19, 2019
    Assignee: GRIFOLS, S.A.
    Inventors: Brett Buno, Terri Journigan, Joann Hotta, Michael Burdick
  • Publication number: 20170022480
    Abstract: A method of purification of non-enveloped or pseudo-enveloped virus produced in vitro uses a composition with at least one detergent. A method of purification can use multiple detergents, and a method of determining the presence and/or level of a non-enveloped or pseudo-enveloped virus in a sample includes treating with at least one detergent.
    Type: Application
    Filed: July 19, 2016
    Publication date: January 26, 2017
    Inventors: BRETT BUNO, TERRI JOURNIGAN, JOANN HOTTA, MICHAEL BURDICK
  • Publication number: 20170022481
    Abstract: Polybrene as an additive in cell culture medium is used in methods for the generation of high-titer hepatitis E virus stocks and assays for titration of hepatitis E virus. A cell culture medium containing polybrene is used for high-titer HEV generation, a method for determining the presence and/or the level of HEV in a sample, and an HEV titration assay using polybrene.
    Type: Application
    Filed: July 19, 2016
    Publication date: January 26, 2017
    Inventors: BRETT BUNO, TERRI JOURNIGAN, JOANN HOTTA, MICHAEL BURDICK
  • Patent number: 9523694
    Abstract: A method identifies atypical antibodies in blood or blood product manufacturing processes that may produce false positives in quality control testing on intermediate or final products.
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: December 20, 2016
    Assignee: GRIFOLS, S.A.
    Inventors: Joann Hotta, Clark Zervos
  • Publication number: 20150132773
    Abstract: A method identifies atypical antibodies in blood or blood product manufacturing processes that may produce false positives in quality control testing on intermediate or final products.
    Type: Application
    Filed: November 22, 2012
    Publication date: May 14, 2015
    Inventors: Joann Hotta, Clark Zervos
  • Patent number: 9023797
    Abstract: Described herein are methods for inactivating viruses using caprylate in solutions containing albumin.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: May 5, 2015
    Assignee: Grifols, S.A.
    Inventors: Wytold Lebing, Doug Burns, Nathan Roth, Joann Hotta
  • Publication number: 20140163101
    Abstract: Described herein are methods for inactivating viruses using caprylate in solutions containing albumin.
    Type: Application
    Filed: July 25, 2013
    Publication date: June 12, 2014
    Applicant: GRIFOLS, S.A.
    Inventors: Wytold Lebing, Doug Burns, Nathan Roth, Joann Hotta
  • Publication number: 20040116676
    Abstract: A method of nanofiltration is provided, comprising passing a solution through at least one nanofiltration membrane having an average pore size of from about 15 nm to about 25 nm under normal flow conditions, wherein the solution components are sufficiently pure and at a concentration that allows the immunoglobulins to pass through at least one nanofiltration membrane. The solutions can contain, for example, immunoglobulins, Factor VIII, or plasmin/plasminogen.
    Type: Application
    Filed: September 25, 2003
    Publication date: June 17, 2004
    Inventors: JoAnn Hotta, Marina N. Korneyeva, Wytold Lebing